Welcome to our dedicated page for EXELIXIS SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.
Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.
Exelixis has a planned Rule 144 sale of 34,278 common shares, to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ. The filing lists an aggregate market value of 1,473,964.28 for these shares.
The shares were acquired as performance shares from the issuer on 01/15/2026, with the same date shown for payment and the nature of payment marked "Not Applicable." The document notes 259,708,689 shares outstanding, giving context for the size of this potential sale, and indicates an approximate sale date of 02/13/2026.
A holder filed a notice of proposed sale under Rule 144 to sell 30,250 shares of common stock of the issuer through Morgan Stanley Smith Barney LLC on 02/13/2026 on NASDAQ. The filing shows an aggregate market value of $1,325,407.81 for these planned sales.
The shares were acquired as restricted stock on 05/31/2025 totaling 21,162 shares with no cash payment noted, and 9,088 shares from a stock option exercise on 02/13/2026 paid in cash. Shares outstanding were 259,708,689 at the time indicated.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report beneficial ownership of 13,658,388 shares of Exelixis, Inc. common stock, representing 5.09% of the class. They hold shared power to vote and dispose of these shares, with no sole voting or dispositive power.
The firms state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Exelixis.
Exelixis, Inc. insider plans Rule 144 sale of common stock. A holder has filed to sell 5,000 shares of Exelixis common stock through Morgan Stanley Smith Barney LLC on or around 02/12/2026 on the NASDAQ, with an aggregate market value of $216,250 at the time of the notice.
The shares were received as a gift from an affiliate, identified as Michael Morrissey/Morrissey Family Trust, on 11/11/2025, with the donor having originally acquired them on 10/02/2019. The filing notes 259,708,689 common shares outstanding, providing a baseline for the size of this planned sale.
Exelixis, Inc. is an oncology-focused biopharma built around its cabozantinib franchise, marketed as CABOMETYX and COMETRIQ for multiple cancers including renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, neuroendocrine tumors and medullary thyroid cancer.
In 2025, Exelixis recorded $2.12 billion in net product revenue from CABOMETYX and COMETRIQ, up about 17% year over year, and earned $179.2 million in cabozantinib royalties from partners Ipsen and Takeda, marking its ninth consecutive profitable year. Collaboration deals generate additional milestones and royalties.
The company remains heavily reliant on CABOMETYX but is building a broad pipeline. Lead candidate zanzalintinib, a next-generation VEGF-receptor TKI, is in multiple late-stage trials across colorectal, renal cell, neuroendocrine tumors and meningioma, with a U.S. NDA accepted for previously treated metastatic colorectal cancer and a PDUFA target date of December 3, 2026.
Additional early-stage programs include small molecule USP1 inhibitor XL309 and several biotherapeutics, such as ADC XB010, bispecific antibody XB628 and TF-targeting ADC XB371. Extensive collaborations with Ipsen, Takeda, Roche, Bristol Myers Squibb, Merck and others support global commercialization of cabozantinib and co-fund development of new regimens.
Exelixis reported stronger results for 2025, with total revenues of $2.32 billion versus $2.17 billion in 2024, driven mainly by its cabozantinib cancer franchise. U.S. cabozantinib net product revenues reached $2.12 billion, and global franchise revenues with partners totaled $2.9 billion.
GAAP net income rose to $782.6 million, or $2.78 diluted EPS, up from $1.76 a year earlier; non-GAAP diluted EPS was $3.08. Fourth quarter diluted EPS was $0.88 GAAP and $0.94 non-GAAP. The company repurchased $264.5 million of stock in Q4 and has retired 76.7 million shares cumulatively.
For 2026, Exelixis guides total revenues to $2.525–$2.625 billion and net product revenues to $2.325–$2.425 billion. The FDA has accepted its NDA for zanzalintinib in previously treated metastatic colorectal cancer, with a PDUFA target date of December 3, 2026, and multiple pivotal zanzalintinib trials are advancing.
Exelixis, Inc. President and CEO Michael Morrissey reported equity compensation activity involving company common stock. On January 15, 2026, he acquired 548,073 shares of common stock at $0 per share through the vesting of a performance-based restricted stock unit award. On the same date, 139,524 shares were withheld at $45.23 per share to cover taxes related to this vesting.
After these transactions, Morrissey held 1,825,241 shares of Exelixis common stock directly. In addition, 1,714,404 shares were held indirectly by the Morrissey Family Living Trust, and 17,728 shares were held indirectly through the Exelixis 401(k) Plan. A separate grant includes 1,690,729 shares that may be issued in the future upon vesting of restricted stock units and performance-based units previously awarded.
Exelixis, Inc. executive Aftab Dana, EVP of Research and Development, reported equity award activity tied to a performance-based restricted stock unit (PSU) grant. On January 15, 2026, 119,578 shares of common stock were acquired at $0 per share upon certification that certain PSU performance criteria were achieved. On the same date, 27,254 shares were withheld at $45.23 per share to cover taxes from this vesting. After these transactions, Dana beneficially owned 733,102 shares of Exelixis common stock directly, which includes 491,096 shares that will be issued upon future vesting of restricted stock units and PSUs granted on March 31, 2025, and also held 5,835 shares indirectly through the Exelixis 401(k) Plan as of January 14, 2026.
Exelixis, Inc. EVP, Commercial Haley J. Patrick reported equity award activity tied to performance-based restricted stock units. On January 15, 2026, 139,508 shares of common stock were acquired at $0 per share upon vesting of a performance-based restricted stock unit award originally granted on April 3, 2023, following the Compensation Committee’s certification that certain performance criteria had been achieved.
On the same date, 32,332 shares were withheld at a price of $45.23 per share to cover taxes related to this PSU vesting. After these transactions, Patrick directly beneficially owned 481,205 shares of Exelixis common stock, which includes 443,784 shares that will be issued upon future vesting of previously granted RSUs and one-time performance stock units awarded on March 31, 2025.
Exelixis, Inc. EVP and CFO Christopher J. Senner reported equity award activity on January 15, 2026. He acquired 149,474 shares of common stock at $0 per share upon vesting of performance-based restricted stock units granted on April 3, 2023, after the compensation committee certified achievement of required performance criteria.
To cover taxes related to this vesting, 40,459 shares were withheld by Exelixis at a price of $45.23 per share. After these transactions, Senner directly beneficially owns 1,076,857 shares of Exelixis common stock, which include 494,177 shares that will be issued upon future vesting of previously granted RSUs and PSUs. He also indirectly holds 2,723 shares through the Exelixis 401(k) plan as of January 14, 2026.